Strategic Capital Advisers’s Merck MRK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
$2.96M Buy
32,506
+2,978
+10% +$264K 2.45% 16
2022
Q1
$2.42M Buy
29,528
+454
+2% +$35.8K 1.85% 31
2021
Q4
$2.23M Sell
29,074
-1,062
-4% -$84.6K 1.6% 33
2021
Q3
$2.26M Buy
30,136
+8,131
+37% +$618K 1.76% 30
2021
Q2
$1.71M Sell
22,005
-645
-3% -$48K 1.41% 35
2021
Q1
$1.67M Sell
22,650
-183
-0.8% -$13.5K 1.45% 35
2020
Q4
$1.78M Buy
22,833
+806
+4% +$61.6K 1.52% 33
2020
Q3
$1.74M Buy
+22,027
New +$1.73M 1.64% 32

Other funds holding MRK

Strategic Capital Advisers's MRK Position: Q2 2022 in Review

Strategic Capital Advisers increased its Merck (MRK) stake by 10% in Q2 2022, buying an estimated $264K and bringing the position to 32,506 shares worth $2.96M. The position accounts for 2.45% of the portfolio, ranked #16.

Strategic Capital Advisers first reported a position in MRK in Q3 2020 and has held it in 8 quarters since. 3,015 funds tracked by Wall St. Rank hold MRK as of Q2 2022.

  • Strategic Capital Advisers held 32,506 shares of Merck worth $2.96M as of Q2 2022.
  • Strategic Capital Advisers bought 2,978 Merck shares in Q2 2022, an estimated $264K.
  • Merck made up 2.45% of Strategic Capital Advisers's portfolio in Q2 2022, its #16 holding.
  • Strategic Capital Advisers first reported a position in Merck in Q3 2020 and has held it in 8 quarters since.
  • 3,015 funds tracked by Wall St. Rank held Merck as of Q2 2022.

Based on Strategic Capital Advisers's 13F filing for Q2 2022, filed 18 Jul 2022.